Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Symptomatic intracranial hypertension and prolonged hypocalcemia following treatment of Paget's disease of the skull with zoledronic acid.

Ferraz-de-Souza B, Martin RM, Correa PH.

J Bone Miner Metab. 2013 May;31(3):360-5. doi: 10.1007/s00774-012-0395-8. Epub 2012 Oct 18.

PMID:
23076294
2.
3.

Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.

Whitson HE, Lobaugh B, Lyles KW.

Bone. 2006 Oct;39(4):954-8. Epub 2006 Jun 12.

PMID:
16769264
4.

Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment.

Polyzos SA, Anastasilakis AD, Makras P, Terpos E.

Exp Clin Endocrinol Diabetes. 2011 Oct;119(9):519-24. doi: 10.1055/s-0031-1284365. Epub 2011 Aug 2. Review.

PMID:
21811962
5.

Persistent effect of zoledronic acid in Paget's disease.

Tziomalos K, Florentin M, Krikis N, Perifanis V, Karagiannis A, Harsoulis F.

Clin Exp Rheumatol. 2007 May-Jun;25(3):464-6.

PMID:
17631747
6.

Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.

Polyzos SA, Anastasilakis AD, Litsas I, Efstathiadou Z, Kita M, Arsos G, Moralidis E, Papatheodorou A, Terpos E.

J Bone Miner Metab. 2010 Nov;28(6):706-12. doi: 10.1007/s00774-010-0198-8. Epub 2010 Jun 9.

PMID:
20533067
7.

Diagnosis and treatment of Paget's disease of bone: a mini-review.

Ferraz-de-Souza B, Correa PH.

Arq Bras Endocrinol Metabol. 2013 Nov;57(8):577-82. Review.

8.

Medical management of Paget's disease of bone: indications for treatment and review of current therapies.

Siris ES, Lyles KW, Singer FR, Meunier PJ.

J Bone Miner Res. 2006 Dec;21 Suppl 2:P94-8. Review.

9.

Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D.

N Engl J Med. 2005 Sep 1;353(9):898-908.

10.

A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.

Abelson A.

Curr Med Res Opin. 2008 Mar;24(3):695-705. doi: 10.1185/030079908X260899. Epub 2008 Jan 25. Review.

PMID:
18226324
11.

Vertex extradural hematoma in association with Paget's disease of the skull.

Ramesh VG, Deiveegan K, Soundappan V.

Neurol India. 2005 Mar;53(1):115-6.

12.

Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.

Keating GM, Scott LJ.

Drugs. 2007;67(5):793-804. Review.

PMID:
17385948
13.

Effect of bisphosphonate treatment in patients with Paget's disease of the skull.

Donáth J, Krasznai M, Fornet B, Gergely P Jr, Poór G.

Rheumatology (Oxford). 2004 Jan;43(1):89-94. Epub 2003 Aug 15.

PMID:
12923287
14.

Paget's disease of bone and osteonecrosis.

Seehra J, Sloan P, Oliver RJ.

Dent Update. 2009 Apr;36(3):166-8, 171-2.

PMID:
19480105
15.

Effect of zoledronic acid on serum calcium in Paget's disease patients after educational strategies to improve calcium and vitamin D supplementation.

Tucci JR, Bone HG, Su G, Tan M, Ozturk ZE, Aftring P.

Ther Adv Endocrinol Metab. 2015 Aug;6(4):155-62. doi: 10.1177/2042018815579020.

16.

[Treatment of Paget's disease of bone with zoledronic acid].

Body JJ, Sternon J.

Rev Med Brux. 2005 Nov-Dec;26(6):513-7. Review. French.

PMID:
16454155
18.

Intravenously administered pamidronate in the treatment of Paget's disease of bone.

Tucci JR, Bontha S.

Endocr Pract. 2001 Nov-Dec;7(6):423-9. Erratum in: Endocr Pract 2002 Jan-Feb;8(1):78.

PMID:
11747277
20.

Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report.

Noriega Aldave AP, Jaiswal S.

J Med Case Rep. 2014 Oct 23;8:353. doi: 10.1186/1752-1947-8-353.

Supplemental Content

Support Center